Pharmaceutical Technology on MSN
GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal
HMPL-A830 is an antibody-targeted therapy conjugate (ATTC) that selectively delivers a therapeutic drug to cancer cells, ...
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two ...
Medicus Pharma (MDCX) on Thursday announced a licensing agreement worth up to $1B with Pfizer (PFE) to jointly develop and ...
The conjugate training method is a weightlifting program that’s primarily designed to build strength. It’s sometimes referred to as the Westside-Barbell Conjugate Method or Westside’s Conjugate Method ...
Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in ...
A830, an experimental antibody conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors, in a deal worth up to ...
An effective, affordable, multivalent meningococcal conjugate vaccine is needed to prevent epidemic meningitis in the African meningitis belt. Data on the safety and immunogenicity of NmCV-5, a ...
Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced the submission of a Clinical Trial Application (CTA) to European regulatory authorities to conduct a pivotal clinical trial for TSY-110. TSY ...
Group A meningococci are the source of major epidemics of meningitis in Africa. An affordable, highly immunogenic meningococcal A conjugate vaccine is needed. We conducted two studies in Africa to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results